

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2025

DIAMEDICA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

British Columbia  
(State or other jurisdiction  
of incorporation)

001-36291  
(Commission  
File Number)

Not Applicable  
(IRS Employer  
Identification No.)

301 Carlson Parkway, Suite 210  
Minneapolis, Minnesota  
(Address of principal executive offices)

55305  
(Zip Code)

(763) 496-5454  
(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Voting common shares, no par value per share	DMAC	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective August 4, 2025, Lorianne Masuoka, M.D. resigned as Chief Medical Officer of DiaMedica Therapeutics Inc. (the “Company”), effective as of August 4, 2025, for personal reasons.

In connection with Dr. Masuoka’s departure, the Company and Dr. Masuoka entered into a separation and release agreement (“Separation Agreement”) effective August 4, 2025, providing for the continuation of health benefits to Dr. Masuoka through October 2026.

The foregoing is a summary description of the terms and conditions of the Separation Agreement and is qualified in its entirety by reference to the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

**Item 7.01 Regulation FD Disclosure.**

The Company announced the appointment of Julie Krop, M.D. as Chief Medical Officer of the Company in a press release issued on August 6, 2025, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01 and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for the purposes of Section 18 of the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any other filing by the Company under the Exchange Act or the United States Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.

**Item 8.01 Other Events.**

On July 31, 2025, the Company appointed Julie Krop, M.D., to serve as Chief Medical Officer of the Company, effective as of August 11, 2025. Over the course of her career in biotech and pharmaceuticals, Dr. Krop more than 20 years of experience as a strategic physician executive with leadership experience spanning multiple therapeutic and orphan indications in both pre-commercial and commercial organizations. She joins DiaMedica from PureTech Health, where she was CMO and Head of Development, leading multiple rare disease programs from preclinical development through Phase 2 trials. Prior, she served as CMO at Freeline Therapeutics, where she helped drive a successful IPO and oversaw three clinical stage gene therapy programs. Before that, Dr. Krop was CMO and executive vice president at AMAG Pharmaceuticals, where she was involved in the approval of three drugs and worked on the development of an orphan drug candidate for the treatment of severe preeclampsia. Previously, Dr. Krop has held senior development roles at Vertex Pharmaceuticals, Stryker Regenerative Medicine, Peptimmune, Millennium Pharmaceuticals, and Pfizer. Dr. Krop received her MD from Brown University School of Medicine and completed her residency at Georgetown University Hospital. She also completed fellowships in epidemiology, clinical trial design and endocrinology at Johns Hopkins School of Medicine. Dr. Krop is board-certified in Endocrinology.

---

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit is furnished herewith:

<b>Exhibit Number</b>	<b>Description</b>
10.1	<a href="#">Separation Agreement between DiaMedica Therapeutics Inc. and Lorianne Masuoka, M.D., dated August 5, 2025.</a>
99.1	<a href="#">Press release dated August 6, 2025, announcing the appointment of Julie Krop, M.D.</a>
104	Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DIAMEDICA THERAPEUTICS INC.**

By: /s/ Scott Kellen

Scott Kellen

Chief Financial Officer and Secretary

Dated: August 6, 2025

**CONFIDENTIAL SEPARATION AGREEMENT**

This Confidential Separation Agreement ("Agreement") and the Release, which is attached hereto and incorporated by reference as Exhibit A ("Release"), are made by and between Lorianne Masuoka ("Employee"), and DiaMedica USA Inc., its affiliates, related or predecessor corporations, parent, subsidiaries, successors, and assigns ("Employer").

Employee and Employer are sometimes referred to herein individually as "Party" and collectively referred to as "Parties".

The Employer and Employee wish to end their employment relationship in an honorable, dignified, and orderly fashion. Toward that end, the Parties have agreed to separate according to the following terms.

Employee does not believe that she has any claims against Employer. Nevertheless, the Parties agree to resolve any actual and potential claims arising out of Employee's employment with and separation from Employer by entering into this Agreement.

IN CONSIDERATION OF THIS AGREEMENT AND RELEASE, THE LEGAL SUFFICIENCY OF WHICH THE PARTIES ACKNOWLEDGE, THE PARTIES AGREE AS FOLLOWS:

1. Termination. Pursuant to her termination, Employee's employment ends on August 4, 2025. ("Termination Date").
  2. Consideration (Cobra Continuance). If Employee executes and delivers to Employer this Agreement and Release within twenty-one (21) days after the Termination Date, and the Rescission Periods specified herein have expired (without any actual rescission by Employee), then as consideration for Employee's promises and obligations under this Agreement and Release, and subject to the terms and conditions of this Agreement, Employer will pay the following Consideration:
    - a. The Company will pay your Cobra benefits until October 30, 2026 at which time you will be eligible for Medicare.
    - b. Employee agrees Employee is not entitled to the Consideration (and will forfeit all rights to the Consideration offered in this Agreement) if Employee: (i) does not return to Employer a signed copy of this Agreement and Release, releasing any and all actual or potential claims which may have arisen at any time during Employee's employment with or termination from employment with Employer, within twenty-one (21) days after the Termination Date; (ii) revokes, or attempts to revoke, Employee's release of any claims under this Agreement; or (iii) violates the terms of this Agreement.
    - c. The Parties intend that the Consideration provided under this Agreement will comply, in form and operation, with an exception to or exclusion from the requirements of Internal Revenue Code §409A and this Agreement will be construed and administered in a manner that is consistent with and gives effect to such intention. The Consideration is provided upon Employee's termination of employment with Employer (and all its affiliates) that would be considered a "separation from service" under Section 409A of the Code and the Consideration is intended to be exempt from the requirements of Code §409A because such payments are short-term deferrals under Treas. Reg. §1.409A-1(b)(4) and also provided under a separation pay plan within the meaning of Treas. Reg. §1.409A-1(b)(9).
-

3. Termination of Benefits; COBRA. Except as otherwise provided by this Agreement, Employee's participation in Employer's employee benefits, bonus, and all other compensation or commission plans, will terminate on the Termination Date, unless otherwise provided by law, or benefit plan. Employee will receive no compensation or benefits under such plans, except as specifically provided in Section 2 of this Agreement. Nothing in this Agreement affects Employee's rights to timely elect continued coverage under Employer's group health plans (such as medical or dental) pursuant to section 4980B of the Internal Revenue Code of 1986, as amended ("COBRA"), in accordance with ordinary plan practices. Employee will receive a separate COBRA Notice from the group health plan(s) relating to the procedures for electing such coverage.

4. Execution of Agreement and Release of all Claims. Employee agrees to fully execute this Agreement, and the Release attached as Exhibit A, releasing any and all actual or potential claims which may have arisen at any time during Employee's employment with or termination from employment with Employer. Employee's failure to execute this Agreement and/or Release within twenty-one (21) days after the Termination Date, or if Employee rescinds this Agreement or Release within the applicable Rescission Periods, will terminate this Agreement, and the Parties' respective rights and obligations under this Agreement.

5. Time to Consider: Voluntary and Knowing Action. Employee acknowledges Employee has had at least 21 days to consider the terms of this Agreement and the Release but agrees that in no event will Employee execute this Agreement and Release prior to Employee's Termination Date. Employee acknowledges that Employee has voluntarily and knowingly entered into the Agreement and the Release with full knowledge of its consequences. Employee acknowledges that the Agreement and Release have been written in a way that Employee understands. Employee acknowledges that she has had the opportunity to be represented by legal counsel during the negotiation and execution of this Agreement and Release, and that Employee understands that Employee will be fully bound by this Agreement and Release.

6. Certification of Non-Retention of Employer Property. As a condition of the Consideration described in Section 2 of this Agreement, Employee certifies that Employee has returned and not retained, in any form or format, all Employer documents, data, and other property in Employee's possession or control and certifies that Employee has permanently deleted from any electronic media in Employee's possession, custody, or control (such as computers, smart phones, cell phones, hand-held devices, back-up devices, zip drives, etc.) or to which Employee has or may have had access (such as remote e-mail exchange servers, back-up servers, off-site storage, etc.), all documents or electronically stored images of Employer documents, data and other property, including writings, drawings, graphs, charts, sound recordings, images, and other data or data compilations stored in any medium from which such information can be obtained. Employee agrees to provide Employer with a list of any documents that Employee created or is otherwise aware that are password-protected and the password(s) necessary to access such password-protected documents. For purposes of this Agreement, "documents, data, and other property" includes, without limitation, drawings, orders, files, documents, notes, computers, laptop computers, fax machines, cell phones, smart devices, access cards, fobs, keys, reports, manuals, records, correspondence and/or other documents or materials related to Employer's business that Employee has compiled, generated or received while working for Employer, including all electronically stored information, copies, samples, computer data, disks, or records of such materials and all Confidential Information (as hereinafter defined). Employee agrees to return DiaMedica property located at her residence before the Consideration noted in Section 2.a. is remitted, including but not limited to the Employer property listed in Exhibit C.

---

7. Cooperation. In exchange for the Consideration to be paid by Employer and other undertakings of Employer stated in this Agreement, Employee agrees to be available upon reasonable notice from Employer, with or without a subpoena, to be interviewed, review documents or things, give depositions, testify, or engage in other reasonable activities, with respect to matters and/or disputes concerning which Employee has or may have knowledge as a result of or in connection with Employee's employment by Employer. In performing Employee's obligations under this Section 6 to testify or otherwise provide information, Employee will honestly, truthfully, forthrightly, and completely provide the information requested. Employee will comply with this Agreement upon notice from Employer that Employer or its attorneys believe that Employee's compliance will assist in the resolution of an investigation or the prosecution or defense of claims. Employee understands and agrees that Employer's obligations under this Agreement are contingent upon Employee cooperating with Employer in investigations and litigation.

8. Confidentiality of Agreement. It is the intent of Employer and Employee that the terms of this Agreement be treated as confidential. Employee warrants that Employee has not and agrees that Employee will not in the future disclose the terms of this Agreement, or the terms of the Consideration to be paid by Employer to Employee as part of this Agreement, to any person other than Employee's attorney, tax advisor, spouse, or representatives of any state or federal regulatory agency, who will be bound by the same prohibitions against disclosure as bind Employee, and Employee will be responsible for advising those individuals or agencies of this confidentiality provision. Employee will not provide or allow to be provided to any person this Agreement, or any copies thereof, nor will Employee now or in the future disclose the terms of this Agreement to any person, with the sole exception of communications with Employee's spouse, attorney and tax advisor, unless otherwise ordered to do so by a court or agency of competent jurisdiction.

9. Non-Disparagement. Unless otherwise required by law, including but not limited to under the National Labor Relations Act if applicable to Employee, or unless it is in the context of an Equal Employment Opportunity Commission ("EEOC") or other civil rights or other government enforcement agency investigation or proceeding, Employee agrees that she will make no critical, disparaging or defamatory comments regarding Employer or any Released Party (as defined in the Release), in any respect or make any comments concerning the conduct or events which precipitated Employee's separation. Furthermore, Employee agrees not to assist or encourage in any way any individual or group of individuals to bring or pursue a lawsuit, charge, complaint, or grievance, or make any other demands against Employer or any Released Party. This provision does not prohibit Employee from participating in an EEOC or other civil rights or other government enforcement agency charge, investigation or proceeding, or from providing testimony or documents pursuant to a lawful subpoena or as otherwise required by law. Employer agrees that it will make no critical, disparaging or defamatory comments regarding Employee, in any respect or make any comments concerning the conduct or events which precipitated Employee's separation.

10. Exclusions and Limitations on Confidentiality of Agreement and Non-Disparagement Provisions. The Parties agree that nothing in this Agreement, including Sections 8 and 9, prohibits them or may be read to prohibit them from:

- A. filing a charge with an administrative agency, including the National Labor Relations Board and/or participating in a charge filed by another individual or agency, or participating or testifying in an agency investigation.
  - B. exercising protected rights under Section 7 of the National Labor Relations Act, if applicable, where "employees" (within the meaning of the Act) may, among other things, communicate through any means with any person or entity to discuss wages and terms and conditions of employment and/or exercise any other rights to engage in activity protected under Section 7 of the National Labor Relations Act;
  - C. reporting any good faith allegation of unlawful employment practices to any appropriate federal, State, or local government agency enforcing labor and employment related discrimination laws.
-

- D. reporting any good faith allegation of criminal conduct to any appropriate federal, state, or local official.
- E. participating in a proceeding with any appropriate federal, state, or local government agency enforcing discrimination laws.
- F. making any truthful statements or disclosures required by law, regulation, or legal process; and
- G. requesting or receiving confidential legal advice regarding this Agreement or otherwise.

11. Stipulation of No Charges. Employee affirmatively represents that Employee has not filed nor caused to be filed any charges, claims, complaints, or actions against Employer before any federal, state, or local administrative agency, court, or other forum. Except as expressly provided in this Agreement or required by law, Employee acknowledges and agrees that Employee has been paid all wages, bonuses, compensation, benefits and other amounts that are due, with the exception of any vested right under the terms of a written ERISA-qualified benefit plan. Employee waives any right to any form of recovery or compensation from any legal action, excluding any action claiming this Agreement and Release violate the Age Discrimination in Employment Act (“ADEA”) and/or the Older Workers Benefit Protection Act (“OWBPA”), filed or threatened to be filed by Employee or on Employee’s behalf based on Employee’s employment, terms of employment, or separation from, Employer. Employee understands that any Consideration paid to Employee pursuant to this Agreement may be deducted from any monetary award Employee may receive as a result of a successful ADEA and/or OWBPA claim or challenge to this Agreement and Release. This does not preclude Employee from eligibility for unemployment benefits and does not preclude or obstruct Employee’s right to file a charge with the Equal Employment Opportunity Commission.

12. Agreement Not to Seek Future Employment. Employee agrees that Employee will never knowingly seek nor accept employment with Employer, nor any other entity owned by Employer, either directly or through a consulting firm.

13. Withholding for Amounts Owed to Employer. Execution of this Agreement will constitute Employee’s authorization for Employer to make deductions from Employee’s Consideration, for Employee’s indebtedness to Employer, or to repay Employer for unaccrued vacation or other Paid Time Off already taken, Employee purchases, wage or benefit overpayment, or other Employer claims against Employee, if any and to the extent permitted by applicable law.

14. Non-Admissions. The Parties expressly deny any and all liability or wrongdoing and agree that nothing in this Agreement or the Release will be deemed to represent any concession or admission of such liability or wrongdoing or any waiver of any defense.

15. Governing Law; Consent to Personal Jurisdiction. The laws of the State of Minnesota will govern this Agreement without regard to conflict of laws principles. The Parties each hereby consent to the personal jurisdiction of the state courts located in Hennepin County, State of Minnesota, and the federal district court sitting in Hennepin County, State of Minnesota, if that court otherwise possesses jurisdiction over the matter, for any legal proceeding concerning or related to this Agreement.

16. Remedies. The Certification of Non-Retention of Employer Property and Non-Disparagement provisions of this Agreement have substantially induced Employer to enter into this Agreement. Any violation by the Employee of such provisions of this Agreement shall obligate the Employee to return to Employer the Consideration which she has received pursuant to this Agreement and shall entitle Employer to bring a legal action for damages and other appropriate relief, and to recover the attorneys’ fees and costs which Employer incurs in the course of enforcing its rights under this Agreement against the Employee.

---



If to Employee: Lorianne Masuoka  
142 Beverly Road  
Chestnut Hill, MA 02467

23. Waivers. No failure or delay by either Party in exercising any right or remedy under this Agreement will waive any provision of this Agreement.
24. Entire Agreement. Except for any continuing, post-employment obligations under this Agreement or Employee's Employee Agreement attached hereto as Exhibit B, this Agreement and the attached Release and Exhibits B and C are the entire agreement between Employer and Employee relating to Employee's employment and separation.
25. Miscellaneous. This Agreement may be executed simultaneously in counterparts, each of which will be an original, but all of which will constitute but one and the same agreement.

*{Remainder of page intentionally left blank}*

---

**Lorianne Masuoka**

/s/ Lorianne Masuoka

---

Dated: August 4, 2025

---

**DIAMEDICA USA INC.**

By: /s/ Scott Kellen

---

It's: Chief Financial Officer

---

Dated: August 4, 2025

---

---

**EXHIBIT A**

**RELEASE**

---

**EXHIBIT B**

**EMPLOYMENT AGREEMENT**

---

**EXHIBIT C – RETURN OF DIAMEDICA PROPERTY**



## **DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer**

**Minneapolis, Minnesota – August 6, 2025 (Business Wire)** – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons.

“We are pleased to welcome Dr. Krop to our executive leadership team,” said Rick Pauls, President and CEO of DiaMedica. “Her extensive experience in the biopharma industry and track record of advancing innovative therapeutics from proof of concept to approval will be invaluable to our team as we advance toward late-stage clinical development of DM199. Additionally, Dr. Krop’s previous experience in preeclampsia drug development will be beneficial as we work to provide a treatment for this significant unmet need. On behalf of the DiaMedica team, I thank Lorianne for her guidance and dedication, which helped position DiaMedica for success. We wish her the best in her future endeavors.”

Dr. Krop added, “I’m excited to join DiaMedica at such a pivotal time in its growth. DM199 has the potential to be a fully disease-modifying therapy for patients with preeclampsia, as demonstrated by the recent Phase 2 Part 1a interim trial results. I look forward to helping guide the company’s clinical development strategy as we advance this first in class drug candidate into later stage development for both preeclampsia and acute ischemic stroke – two areas of urgent unmet need where no approved treatments currently exist.”

Dr. Krop has more than 20 years of experience as a strategic physician executive with leadership experience spanning multiple therapeutic and orphan indications in both pre-commercial and commercial organizations. She joins DiaMedica from PureTech Health, where she was CMO and Head of Development, leading multiple rare disease programs from preclinical development through Phase 2 trials. Prior, she served as CMO at Freeline Therapeutics, where she helped drive a successful IPO and oversaw three clinical stage gene therapy programs. Before that, Dr. Krop was CMO and Executive Vice President at AMAG Pharmaceuticals, where she was involved in the approval of three drugs and worked on the development of an orphan drug candidate for the treatment of severe preeclampsia. Previously, Dr. Krop has held senior development roles at Vertex Pharmaceuticals, Stryker Regenerative Medicine, Peptimmune, Millennium Pharmaceuticals, and Pfizer. Dr. Krop received her MD from Brown University School of Medicine and completed her internal medicine residency at Georgetown University Hospital. She also completed fellowships in epidemiology, clinical trial design and endocrinology at Johns Hopkins School of Medicine. Dr. Krop is board-certified in Endocrinology.

### **About DiaMedica Therapeutics Inc.**

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at [www.diamedica.com](http://www.diamedica.com).

---



#### **Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)**

In connection with Dr. Krop's appointment, DiaMedica granted her an inducement stock option to purchase 450,000 shares of DiaMedica's common stock pursuant to the DiaMedica Therapeutics, Inc. 2021 Employment Inducement Incentive Plan. The inducement grant was approved by the Company's compensation committee of the board of directors and will be effective as of Dr. Krop's first date of employment, August 11, 2025, and was a material inducement to her acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of her compensation.

#### **Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management's current expectations. When used in this press release, the words "anticipates," "believes," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "seek," "might," "project," "target," "aim," or "will," the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the Company's expectations regarding the anticipated clinical benefits and success of DM199 for the treatment of preeclampsia and acute ischemic stroke. Such statements and information reflect management's current view and DiaMedica undertakes no obligation to update or revise any of these statements or information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to the clinical expansion into preeclampsia and that trial; regulatory applications and related filing and approval timelines; the possibility of unfavorable results from DiaMedica's other ongoing or future clinical trials of DM199; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; the potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain disruptions on DiaMedica's business and clinical trials; DiaMedica's reliance on collaboration with third parties to conduct clinical trials; DiaMedica's ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia and acute ischemic stroke and the risks identified under the heading "Risk Factors" in DiaMedica's annual report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports, including DiaMedica's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

#### **Corporate Contact:**

Scott Kellen, Chief Financial Officer  
(763) 496-5118 | [skellen@diamedica.com](mailto:skellen@diamedica.com)

#### **Investor Contact:**

Mike Moyer, Managing Director, LifeSci Advisors  
[mmoyer@lifesciadvisors.com](mailto:mmoyer@lifesciadvisors.com)

#### **Media Contact:**

Madelin Hawtin, LifeSci Communications  
[mhawtin@lifescicomms.com](mailto:mhawtin@lifescicomms.com)

Source: DiaMedica Therapeutics Inc.  
*Released August 6, 2025*